19 results
Aimovig (erenumab-aooe)
(erenumab-aooe)Amgen Inc
Usage: AIMOVIG is indicated for the preventive treatment of migraine in adults.
Amjevita (adalimumab-atto)
(adalimumab-atto)Amgen Inc
Usage: AMJEVITA is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients. It can be used alone or with DMARDs.
Avsola (infliximab-axxq)
(infliximab-axxq)Amgen Inc
Usage: AVSOLA is indicated for treating moderately to severely active Crohn's disease and ulcerative colitis in adults and pediatric patients (6+ years), along with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis in adults, particularly for those who have inadequate responses to conventional therapies.
Bkemv (eculizumab-aeeb)
(eculizumab-aeeb)Amgen Inc
Usage: BKEMV is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody positive. Not for Shiga toxin E. coli related HUS.
Blincyto (blinatumomab)
(blinatumomab)Amgen Inc
Usage: BLINCYTO is indicated for treating CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients aged one month and older. It is used for those with minimal residual disease (MRD), relapsed or refractory disease, and during the consolidation phase of multiphase chemotherapy.
Corlanor (ivabradine)
(ivabradine)Amgen Inc
Usage: Corlanor is indicated for reducing hospitalization risk in adults with stable, symptomatic chronic heart failure (LVEF ≤ 35%) and elevated heart rates, either on maximally tolerated beta-blockers or with contraindications. It’s also used to treat stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients aged 6 months and older.
Evenity (romosozumab-aqqg)
(romosozumab-aqqg)Amgen Inc
Usage: EVENITY is indicated for treating osteoporosis in postmenopausal women at high fracture risk, defined by prior osteoporotic fractures or multiple risk factors, and for those who failed or are intolerant to other therapies. Use is limited to 12 monthly doses due to a waning anabolic effect.
Imdelltra (amg757) (tarlatamab-dlle)
(Tarlatamab-dlle)Amgen Inc
Usage: IMDELLTRA is indicated for adults with extensive stage small cell lung cancer (ES-SCLC) that has progressed after platinum-based chemotherapy. This approval is accelerated and depends on the verification of clinical benefit in future trials.
Imlygic (talimogene laherparepvec)
(talimogene laherparepvec)Amgen Inc
Usage: IMLYGIC is indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal melanoma lesions that recur after initial surgery. It does not improve overall survival or address visceral metastases.
Lumakras (sotorasib)
(sotorasib)Amgen Inc
Usage: LUMAKRAS is indicated for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior systemic therapy, and for those with KRAS G12C-mutated metastatic colorectal cancer (mCRC) in combination with panitumumab following prior chemotherapy.